Chen, Hongrui
Sun, Bin
Xia, Wenwen
Qiu, Yajing
Gao, Wei
Hua, Chen
Lin, Xiaoxi
Funding for this research was provided by:
Major and Key Cultivation Projects of Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine (JYZP005, JYZP005, JYZP005, JYZP005)
Shanghai Sailing Program (22YF1421900, 22YF1421900, 22YF1421900)
Treatment and mechanism of PI3K/mTOR dual-target inhibitor (WX390) on PIK3CA-related overgrowth spectrum (JYWO22075, JYWO22075, JYWO22075)
Rare Disease Registration Platform of Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine (JYHJB02, JYHJB02)
Article History
Received: 22 January 2024
Accepted: 27 January 2024
First Online: 20 February 2024
Declarations
:
: The study was approved by the Ethics Board of Shanghai Ninth Hospital, Shanghai Jiaotong University of Medicine (SH9H-2023-T329-1). Written informed consent forms were signed by patients whose photographs were presented in this study.
: The consent for publication was acquired from patients or patients’ parents.
: The authors declare no competing interests.